Appeal | Project documents | Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [ID6261] | Guidance | NICE

Notice of Appeal

Molnupiravir, remdesivir and tixagevimab plus cilgavimab for treating COVID-19 [ID6261] (previously part of ID4038 - Therapeutics for people with COVID-19)

This appeal hearing will hear appeals against the Final Draft Guidance for the above technologies by the following organisations:

AstraZeneca
Gilead Sciences
Merck Sharp & Dohme

The appeal panel will convene on Tuesday 2 May and Wednesday 3 May 2023 at 10.00am via Zoom to hear oral representations from the appellants.

AstraZeneca : Appeal letter ^{MSWord 43 KB} 02 May 2023
Gilead : Appeal letter ^{MSWord 188 KB} 02 May 2023
Merck Sharp & Dohme : Appeal letter ^{PDF 2.01 MB} 02 May 2023
Gilead : Scrutiny letter ^{MSWord 93 KB} 02 May 2023
Merck Sharp & Dohme : Scrutiny letter ^{MSWord 87 KB} 02 May 2023
Gilead : Response to scrutiny letter ^{MSWord 147 KB} 02 May 2023
Merck Sharp & Dohme : Response to scrutiny letter ^{PDF 293 KB} 02 May 2023
Gilead : Final scrutiny letter ^{MSWord 64 KB} 02 May 2023
Merck Sharp & Dohme : Final scrutiny letter ^{MSWord 70 KB} 02 May 2023
Appeal decision ^{PDF 773 KB} 05 July 2023